Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Methylhomatropine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 5/20 | 0.97 |
| ▸ | CHRM1 known ✓ | P11229 | 4/20 | 0.97 |
| ▸ | CHRM3 known ✓ | P20309 | 4/20 | 0.71 |
| ▸ | CHRM4 known ✓ | P08173 | 3/20 | 0.62 |
| ▸ | CHRM5 known ✓ | P08912 | 3/20 | 0.62 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.74 |
| ▸ | BLM | P54132 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.63 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylhomatropine SCHEMBL29555824 | 1.00 | CHRM2 (0.97) | CHRM2CHRM1PABPC1CHRM3BLM | |
| Methylhomatropine SCHEMBL20659943 | 1.00 | CHRM2 (0.97) | CHRM2CHRM1PABPC1CHRM3BLM | |
| Methylhomatropine SCHEMBL613580 | 1.00 | CHRM2 (0.97) | CHRM2CHRM1PABPC1CHRM3BLM | |
| Methylhomatropine SCHEMBL17179980 | 0.99 | CHRM2 (1.00) | CHRM2CHRM1PABPC1CHRM3BLM | |
| Methylhomatropine SCHEMBL30516140 | 0.99 | CHRM2 (1.00) | CHRM2CHRM1PABPC1CHRM3BLM | |
| Methylhomatropine SCHEMBL16784195 | 0.99 | CHRM2 (1.00) | CHRM2CHRM1PABPC1CHRM3BLM | |
| Methylatropine SCHEMBL1321572 | 0.83 | BLM (1.00) | CHRM2CHRM1PABPC1CHRM3BLM | |
| Methylatropine SCHEMBL30647266 | 0.83 | BLM (1.00) | CHRM2CHRM1PABPC1CHRM3BLM | |
| Phenactropinium SCHEMBL29387827 | 0.82 | CHRM2 (0.70) | CHRM2CHRM1PABPC1CHRM3BLM | |
| Phenactropinium SCHEMBL8916468 | 0.82 | CHRM2 (0.70) | CHRM2CHRM1PABPC1CHRM3BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1072 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115028628-B | RSV-F protein small molecule inhibitor and application thereof in preparation of medicines for preventing and treating RSV infection | 中南大学 | 2023-10-10 | — | — | CN | claimed |
| EP-4178948-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2023-05-17 | — | — | EP | claimed |
| EP-4154879-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NICOTINE WITHDRAWAL SYMPTOMS | Korea Institute of Science and Technology (KR) | 2023-03-29 | — | — | EP | claimed |
| WO-2022023496-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2022-02-03 | — | — | WO | claimed |
| US-20200397702-A1 | PHARMACEUTICAL COMPOSITIONS | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2020-12-24 | — | — | US | claimed |
| EP-3493789-A2 | INTRANASAL PHARMACEUTICAL POWDER COMPOSITIONS | Shin Nippon Biomedical Laboratories, Ltd. (JP) | 2019-06-12 | — | — | EP | claimed |
| US-10149822-B2 | Compositions and methods for combination ingredient delivery | THE FIX, LLC (US) | 2018-12-11 | — | — | US | claimed |
| US-10123996-B2 | Macrocyclic lactone compounds and methods for their use | ELIXIR MEDICAL CORPORATION (US) | 2018-11-13 | — | — | US | claimed |
| WO-2018025089-A2 | PHARMACEUTICAL COMPOSITIONS | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2018-02-08 | — | — | WO | claimed |
| CN-106432221-B | A kind of process for purification of Homatropine Methylbromide | 湖北百科亨迪药业有限公司 | 2018-01-12 | — | — | CN | claimed |
| WO-2006058249-A9 | METHODS AND COMPOSITIONS FOR DETERRING ABUSE OF ORALLY ADMINISTERED PHARMACEUTICAL PRODUCTS | ACURA PHARMACEUTICALS INC (US) | 2006-07-20 | — | — | WO | claimed |
| WO-2006058249-A2 | METHODS AND COMPOSITIONS FOR DETERRING ABUSE OF ORALLY ADMINISTERED PHARMACEUTICAL PRODUCTS | ACURA PHARMACEUTICALS, INC. (US) | 2006-06-01 | — | — | WO | claimed |
| US-20060110327-A1 | Methods and compositions for deterring abuse of orally administered pharmaceutical products | ACURA PHARMACEUTICALS, INC. | 2006-05-25 | — | — | US | claimed |
| EP-1480677-A2 | COMPOSITION FOR STABILIZING HYALURONIC ACID | IOLTECH (FR) | 2004-12-01 | — | — | EP | claimed |
| US-20030133986-A1 | Compositions for stabilizing poly (carboxylic acids) | TSAO FU-PAO (US) | 2003-07-17 | — | — | US | claimed |
| WO-2003043660-A2 | COMPOSITION FOR STABILIZING HYALURONIC ACID | NOVARTIS AG (CH) | 2003-05-30 | — | — | WO | claimed |
| EP-1233761-A1 | OSMOTIC DOSAGE FORM COMPRISING FIRST AND SECOND COATS | ALZA Corporation (US) | 2002-08-28 | — | — | EP | claimed |
| WO-2001037815-A1 | OSMOTIC DOSAGE FORM COMPRISING FIRST AND SECOND | ALZA CORPORATION (US) | 2001-05-31 | — | — | WO | claimed |
| US-5008111-A | Pretreating skin with anticholinergic quaternary ammonium salt to suppress perspiration | SCHERING CORPORATION (US) | 1991-04-16 | — | — | US | claimed |
| US-4824676-A | ANTICHOLINERGIC AGENT TO SUPPRESS PERSPIRATION | SCHERING CORPORATION (US) | 1989-04-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10123996-B2 | Macrocyclic lactone compounds and methods for their use | CHRM2, CHRM1, CHRM5 | CHRM2 1/4885CHRM1 2/4885CHRM3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.